Phase 1 × Intraocular Lymphoma × Rituximab × Clear all
NCT02168907 2018-07-02

CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Wake Forest University Health Sciences

Phase 1 Terminated
1 enrolled
NCT00416923 2015-02-16

Intrathecal Rituximab in Treating Patients With Recurrent CNS Lymphoma

University of California, San Francisco

Phase 1 Completed
10 enrolled